News Releases

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
Oct 01, 2018DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial OfficerPrinter Friendly Version
Sep 25, 2018DURECT to Present at the Cantor Fitzgerald Global Healthcare ConferencePrinter Friendly Version
Sep 18, 2018DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in TaiwanPrinter Friendly Version
Aug 30, 2018DURECT Announces Receipt of $5 Million Milestone Payment from IndiviorPrinter Friendly Version
Aug 27, 2018DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
Aug 06, 2018DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CIIPrinter Friendly Version
Aug 01, 2018DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Jul 30, 2018DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in AdultsPrinter Friendly Version
Jul 24, 2018DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference CallPrinter Friendly Version
Jun 26, 2018Results of FDA Advisory Committee Meeting for REMOXY® ERPrinter Friendly Version
May 09, 2018DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)Printer Friendly Version
May 02, 2018DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
Apr 25, 2018DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic HepatitisPrinter Friendly Version
Apr 24, 2018DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference CallPrinter Friendly Version
Mar 29, 2018DURECT Corporation to Host Key Opinion Leader Call on Alcoholic HepatitisPrinter Friendly Version
Mar 20, 2018DURECT Announces FDA Advisory Committee Meeting for REMOXY® ERPrinter Friendly Version
Mar 01, 2018DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of ProgramsPrinter Friendly Version
Feb 26, 2018DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)Printer Friendly Version
Feb 22, 2018DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference CallPrinter Friendly Version
Feb 20, 2018DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)Printer Friendly Version
Feb 14, 2018DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain TherapeuticsPrinter Friendly Version